(AAN) MS Outcomes Assessment Consortium

 
Post new topic   Reply to topic    msspeaks Forum Index -> MS - RESEARCH, ARTICLES, ABSTRACTS, DISCUSSION
View previous topic :: View next topic  
Author Message
agate
Site Admin


Joined: 17 May 2006
Posts: 5694
Location: Oregon

PostPosted: Wed Mar 27, 2013 12:52 pm    Post subject: (AAN) MS Outcomes Assessment Consortium Reply with quote

Presented at the annual AAN conference in San Diego, March 16-23, 2013:

Quote:
[S31.001] The Multiple Sclerosis Outcomes Assessment Consortium: Accelerating Development of Treatments for Multiple Sclerosis

Nicholas LaRocca, New York, NY, Lynn Hudson, Tuscon, AZ, Richard Rudick, Cleveland, OH

OBJECTIVE:

The National Multiple Sclerosis Society (NMSS) has entered into a collaboration with the Critical Path Institute (CPath) to create the Multiple Sclerosis Outcomes Assessment Consortium (MSOAC). Its purpose is to analyze data collected during the course of completed MS clinical trials and observational studies with a goal of qualifying a new clinician- reported outcome measure as a primary disability endpoint for future MS trials.

BACKGROUND:

Successful development of disease-modifying drugs for relapsing forms of MS is a landmark achievement in neurotherapeutics. However, treatments that slow disability progression by inhibiting neural degeneration or promoting regeneration are lacking. This represents a significant unmet medical need.

Effective trial designs based on MRI lesions and relapses will not be optimal studies focused on disability progression. New, validated outcome measures focused on disability will be required. The US FDA has established a pathway to qualify new clinician-reported outcomes measures.

DESIGN/METHODS:

The MSOAC is a coalition of industry, academia, patient representatives, regulatory and other government agencies, and the NMSS. To achieve the goal, the MSOAC will create tools that will expedite and benefit the field of MS therapeutics. These include a pooled clinical trial database and a CDISC therapeutic data standard for MS.

In close collaboration with the FDA and European Medicines Agency (EMA), MSOAC members will contribute data and insights to arrive at a scientific consensus on an improved outcome measure. The coalition will be well-positioned for additional collaborative projects aimed at accelerating development of more effective treatments for MS.

RESULTS:

Participating companies, academic investigators, advocacy organizations, and regulatory agencies will be listed; details of the project plan, and current status will be presented.

CONCLUSIONS:

The MSOAC represents a new paradigm in multidisciplinary, collaborative research in which all sectors of the drug development enterprise collaborate in an effort to accelerate progress in developing treatment for progressive MS.

___________________________

Supported by: National Multiple Sclerosis Society.

Category - MS and Related Diseases: Clinical Science

Wednesday, March 20, 2013 4:00 PM

Moderated Platform Session S31: Multiple Sclerosis: Novel Treatments
Back to top
View user's profile Send private message
Display posts from previous:   
Post new topic   Reply to topic    msspeaks Forum Index -> MS - RESEARCH, ARTICLES, ABSTRACTS, DISCUSSION All times are GMT - 7 Hours
Page 1 of 1

 
Jump to:  
You can post new topics in this forum
You can reply to topics in this forum
You can edit your posts in this forum
You can delete your posts in this forum
You cannot vote in polls in this forum
Create your own free forum now!
Terms of Service Purchase Ad Removal Forum Archive Report Abuse